ReviewNature reviews. Clinical oncology2019
Balancing opioid analgesia with the risk of nonmedical opioid use in patients with cancer.
Review in Nature reviews. Clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Advances in prescription drug monitoring program research: a literature synthesis (June 2018 to December 2019).Current opinion in psychiatry · 2020Pooled it
- Cancer-related pain: A bidirectional modulator of cancer progression.Clinical and translational medicine · 2026Review
- Analgesic-loaded NIR-II photothermal hydrogel for efficient anti-infection and precise pain management in wounds.Materials today. Bio · 2026Article
- Article
- Subcutaneous patient-controlled analgesia with hydromorphone for the treatment of refractory cancer pain in older hospitalized patients: a retrospective real-world study.Frontiers in medicine · 2026Article
- Trends in Outpatient Opioid Prescriptions for Cancer Pain Between 2016 and 2021.JCO oncology practice · 2025Article
- Identifying opioid misuse in cancer pain: validation of the prescription opioid misuse index in a multicenter study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Observational
- Frequency and predictors of risk of non-medical opioid use among patients with cancer in a specialized outpatient palliative care clinic.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Antinociceptive Potential ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Analgesic and Anti-Arthritic Potential of Methanolic Extract and Palmatine Obtained fromPharmaceuticals (Basel, Switzerland) · 2024Article
- The Legal Landscape for Opioid Treatment Agreements.The Milbank quarterly · 2024Article
- Clinician Ordering and Management Patterns of Urine Toxicology Results at a Cancer Center.Journal of pain and symptom management · 2024Article
- Trends in new and persistent opioid use in older adults with and without cancer.Journal of the National Cancer Institute · 2024Article
- Opioid Risk Mitigation Practices of Interprofessional Oncology Personnel: Results From a Cross-Sectional Survey.The oncologist · 2023Article
- Impact of Opioids on Cellular Metabolism: Implications for Metabolic Pathways Involved in Cancer.Pharmaceutics · 2023Review
- Does Opioid Use Disorder Matter for Health Care Utilization Among Lung Cancer Patients? Evidence from U.S. Hospitals During 2016-2020.Clinical drug investigation · 2023Article
- Nonmedical opioid use at the end of life: A tale of addiction and a last wish.Palliative & supportive care · 2023Article
- Article
- Coordinated activity of a central pathway drives associative opioid analgesic tolerance.Science advances · 2023Article
- Health Care Provider Attitudes and Beliefs Toward Nonmedical Opioid Use in Patients with Cancer Pain.Journal of palliative medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current opioid crisis has brought renewed attention and scrutiny to opioid prescriptions. When patients receiving opioid therapy for pain engage in nonmedical opioid use (NMOU) or diversion, untoward consequences can occur. New evidence suggests that patients with cancer might be at a higher risk of NMOU than was previously thought, but clinical evidence still supports the use of opioid analgesics as the gold standard to treat cancer-related pain, creating a dilemma in patient management. Clinicians are encouraged to adopt a universal precautions approach to patients with cancer receiving opioids, which includes screening all patients; discussing the risks, benefits, adverse effects and alternatives of opioid therapy; and providing education on safe use, storage and disposal. Use of urine drug tests, prescription drug monitoring programmes and close observation of behaviours related to opioid use help to ensure treatment adherence, detect NMOU and support therapeutic decision-making. These measures can optimize the risk-benefit ratio while supporting safe opioid use. In this Review, we examine the role of opioids in cancer pain, the risk of substance use disorder and methods to achieve the right balance between the two in order to ensure safe opioid use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.